AtaiBeckley Inc. (ATAI) SEC Filings

AtaiBeckley Inc. (ATAI) reports that Chief Operating Officer Gerd Kochendoerfer’s equity awards were cancelled and cashed out in connection with the merger in which AtaiBeckley became a wholly owned subsidiary of Eli Lilly and Company. On September 11, 2026, stock options covering 1,400,000 shares at a $1.60 exercise price, options covering 675,000 shares at a $3.76 exercise price, and 150,000 restricted stock units were disposed of to the issuer and converted into the right to receive $6.75 in cash per underlying share plus one contingent value right per underlying share, each CVR representing the right to receive up to an aggregate of $2.50 in cash upon specified clinical and regulatory milestones.

AtaiBeckley Inc. (ATAI) completed a merger on September 11, 2026 in which Albali Acquisition Corporation, a subsidiary of Eli Lilly and Company, merged with and into AtaiBeckley, leaving AtaiBeckley as a wholly owned subsidiary of Eli Lilly. At the effective time of the merger, each share of AtaiBeckley common stock converted into the right to receive $6.75 in cash per share plus one contingent value right (CVR) per share, representing the right to receive up to an additional $2.50 in cash per CVR if specified clinical and regulatory milestones are achieved. In connection with this transaction, Chief Medical Officer Craig Kevin James reported dispositions to the issuer of all his directly held common stock and equity awards, including multiple stock option grants and 150,000 restricted stock units, which were cancelled and converted into cash based on the $6.75 value and, for options, the excess of $6.75 over the exercise price, plus one CVR for each underlying share.

AtaiBeckley Inc. (ATAI) completed a merger in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged into AtaiBeckley on September 11, 2026, with AtaiBeckley surviving as a wholly owned subsidiary of Eli Lilly. Chief Accounting Officer Anne Nagengast reported dispositions to the issuer of common stock, stock options and restricted stock units at the merger’s effective time. Each common share converted into the right to receive $6.75 in cash plus one contingent value right (CVR) for up to an additional $2.50 in cash per CVR upon specified milestones. Each outstanding stock option and RSU was cancelled and converted into cash based on the $6.75 reference price plus one CVR per underlying share, so these Form 4 entries reflect automatic cancellation and cash-out of equity awards, not open-market trading, and no Rule 10b5-1 plan is reported.

AtaiBeckley Inc. (ATAI) completed a merger on September 11, 2026 in which Albali Acquisition Corporation merged into the company, leaving it as a wholly owned subsidiary of Eli Lilly and Company. At the effective time, each common share converted into the right to receive $6.75 in cash plus one contingent value right (CVR) per share, with each CVR representing up to an additional $2.50 in cash upon specified clinical and regulatory milestones. On the same date, Chief Legal and Business Officer Barrett Christopher Ryan Cave reported dispositions to the issuer of his common stock, stock options, and restricted stock units, which were cancelled and converted into cash consideration and CVRs in connection with the merger; no Rule 10b5-1 trading plan is reported.

AtaiBeckley Inc. (symbol: ATAI) is the issuer of record for a Form 4 filing submitted to the SEC. Short Glenn Frank reported disposition transactions in this Form 4 filing.

AtaiBeckley Inc. (ATAI) reported that Chief Scientific Officer Short Glenn Frank had his equity in the company cancelled and cashed out on September 11, 2026 in connection with the closing of a merger with a subsidiary of Eli Lilly and Company. At the effective time, his 42,333 shares of common stock were converted into the right to receive $6.75 per share in cash plus one contingent value right (CVR) per share, with each CVR representing up to an additional $2.50 in cash upon achievement of specified milestones. Multiple stock option grants and 150,000 restricted stock units were similarly cancelled and converted into cash based on the $6.75 reference price and into one CVR for each underlying share, so that, after these transactions, he no longer directly held common stock or RSUs.

AtaiBeckley Inc. (ATAI) reported that its Chief Financial Officer, Michael E. Faerm, disposed of all reported equity awards in connection with the closing of a merger in which AtaiBeckley became a wholly owned subsidiary of Eli Lilly and Company. On September 11, 2026, an Albali Acquisition Corporation subsidiary of Eli Lilly merged with AtaiBeckley, with AtaiBeckley surviving as a subsidiary.

At the merger’s effective time, a stock option covering 1,275,000 shares of common stock with a $4.06 exercise price and expiring March 11, 2036 was cancelled and converted into the right to receive cash equal to the number of shares multiplied by the excess of $6.75 over the exercise price per share, plus one contingent value right (CVR) for each underlying share. In addition, 285,000 restricted stock units were cancelled and converted into the right to receive cash equal to the number of shares multiplied by $6.75, plus one CVR per underlying share. Each CVR represents the right to receive up to $2.50 in cash upon achievement, if any, of specified clinical and regulatory milestones. Following these cancellations and conversions, the Form 4 shows no remaining holdings for these awards, and no Rule 10b5‑1 trading plan is reported.

AtaiBeckley Inc. (ATAI) director Laurent Fischer reported issuer dispositions of three stock option awards on September 11, 2026 in connection with the completion of a merger in which AtaiBeckley became a wholly owned subsidiary of Eli Lilly and Company. At the merger’s effective time, each affected option was automatically cancelled and converted into the right to receive cash plus a contingent value right. The cancelled options covered 206,000 shares at a $1.34 exercise price expiring June 13, 2034, 103,000 shares at $2.25 expiring June 26, 2035, and 121,968 shares at $4.50 expiring June 4, 2036.

For each share subject to these options, the holder became entitled to a cash payment equal to the product of the number of shares and the excess of $6.75 over the applicable exercise price, plus one contingent value right per share representing the right to receive up to an additional $2.50 in cash upon specified clinical and regulatory milestones, in each case subject to tax withholding. No Rule 10b5-1 trading plan is reported for these transactions.

AtaiBeckley Inc. (ATAI) director John Francis Hoffman reported the disposition to the issuer of stock options in connection with the company’s merger with Eli Lilly and Company. On September 11, 2026, a total of 206,000 options at a $2.25 exercise price and 121,968 options at a $4.50 exercise price were cancelled at the Merger’s Effective Time and converted into rights to receive cash plus one contingent value right per underlying share, consistent with the merger agreement terms.

AtaiBeckley Inc. (ATAI) reports that director Amir H. Kalali disposed of all reported equity positions in connection with the closing of a merger with Eli Lilly and Company. On September 11, 2026, Albali Acquisition Corporation merged into AtaiBeckley, which became a wholly owned subsidiary of Eli Lilly.

At the merger’s effective time, 4,666 shares of common stock held by the reporting person were converted into the right to receive $6.75 per share in cash plus one contingent value right (CVR) per share, with each CVR representing up to $2.50 in additional cash upon specified clinical and regulatory milestones. In parallel, outstanding stock options covering multiple blocks of shares at exercise prices ranging from $1.34 to $4.50 were cancelled and converted into cash equal to the in-the-money value based on the $6.75 per-share merger price, plus one CVR for each underlying share.